161 related articles for article (PubMed ID: 38193937)
21. Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Schild SE
Oral Oncol; 2016 Jun; 57():40-5. PubMed ID: 27208843
[TBL] [Abstract][Full Text] [Related]
22. Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment.
Ghosh S; Rao PB; Kumar PR; Manam S
Asian Pac J Cancer Prev; 2015; 16(16):7331-5. PubMed ID: 26514533
[TBL] [Abstract][Full Text] [Related]
23. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
24. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Ahn PH; Machtay M; Anne PR; Cognetti D; Keane WM; Wuthrick E; Dicker AP; Axelrod RS
Am J Clin Oncol; 2018 May; 41(5):441-446. PubMed ID: 27391356
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
26. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.
Gómez-Millán J; Toledo MD; Lupiañez Y; Rueda A; Trigo JM; Sachetti A; Medina JA
Clin Transl Oncol; 2013 Apr; 15(4):321-6. PubMed ID: 22911552
[TBL] [Abstract][Full Text] [Related]
27. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI).
Trotti A; Johnson DJ; Gwede C; Casey L; Sauder B; Cantor A; Pearlman J
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):257-61. PubMed ID: 9788402
[TBL] [Abstract][Full Text] [Related]
28. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
[TBL] [Abstract][Full Text] [Related]
29. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT; Zhang Q; Rosenthal DI; List M; Axelrod R; Sherman E; Weber R; Nguyen-Tân PF; El-Naggar A; Konski A; Galvin J; Schwartz D; Trotti A; Silverman C; Singh A; Godette K; Bonner JA; Jones CU; Garden AS; Shenouda G; Matthiesen C; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):687-699. PubMed ID: 27727066
[TBL] [Abstract][Full Text] [Related]
30. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
31. Quality of Life of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving High-Dose Cisplatin Chemotherapy and Radiotherapy.
Visacri MB; Ferrari GB; Dias P; Pimentel R; de Souza CM; Costa AP; de Carvalho Pincinato E; Lima CS; Mazzola PG; Moriel P
South Med J; 2015 Jun; 108(6):343-9. PubMed ID: 26079459
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Gupta S; Khan H; Barik S; Negi MP
Drug Discov Ther; 2013 Feb; 7(1):36-42. PubMed ID: 23524942
[TBL] [Abstract][Full Text] [Related]
33. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
[TBL] [Abstract][Full Text] [Related]
34. Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Karner K; Strojan P; Schild SE
Oral Oncol; 2016 Aug; 59():67-72. PubMed ID: 27424184
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
36. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Maguire PD; Neal CR; Hardy SM; Schreiber AM
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI.
Rinkel RN; Verdonck-de Leeuw IM; Doornaert P; Buter J; de Bree R; Langendijk JA; Aaronson NK; Leemans CR
Eur Arch Otorhinolaryngol; 2016 Jul; 273(7):1849-55. PubMed ID: 26071622
[TBL] [Abstract][Full Text] [Related]
39. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of survival of patients with locally advanced head and neck cancer treated in a single center.
Santos FMD; Viani GA; Pavoni JF
Braz J Otorhinolaryngol; 2021; 87(1):3-10. PubMed ID: 31395491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
